[PDF][PDF] PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in …
…, S Dakhil, B Biesma, M Martinez Aguillo… - Journal of clinical …, 2016 - researchgate.net
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent
pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, …
pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, …
[HTML][HTML] Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics
…, M Zuazo, A Bocanegra, M Gato, M Martínez-Aguillo… - Cancers, 2020 - mdpi.com
Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an
acceleration of tumor growth associated with prompt clinical deterioration. The definitions …
acceleration of tumor growth associated with prompt clinical deterioration. The definitions …
[HTML][HTML] PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
…, B Hernandez-Marin, M Martinez-Aguillo… - International journal of …, 2019 - mdpi.com
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …
[HTML][HTML] Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer
…, I Morilla, J Fernández-Irigoyen, M Martínez-Aguillo… - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy has been positioned as frontline therapy for advanced non-small
cell lung cancer (NSCLC), alone when PD-L1 tumor expression is high, or combined …
cell lung cancer (NSCLC), alone when PD-L1 tumor expression is high, or combined …
[PDF][PDF] The EORTC quality of life questionnaire QLO-C30 (version 3.0): Validation study for spanish prostate cancer patients
JIA Urdaniz, EV Iturre, FA de la Vega… - Archivos espanoles de …, 2008 - redalyc.org
Objective: The EORTC Quality of Life Group has developed a questionnaire for evaluating
Quality of Life in international clinical trials: EORTC QLQ-C30, which is widely used in many …
Quality of Life in international clinical trials: EORTC QLQ-C30, which is widely used in many …
A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients …
…, X Mielgo, L Vilà, J Casal, S Ros, M Martinez Aguillo… - 2021 - ascopubs.org
TPS8581 Background: The results of current studies are considered acceptable evidence to
support the hypothesis of efficacy of the proposed combination of immunotherapy with …
support the hypothesis of efficacy of the proposed combination of immunotherapy with …
Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
…, A Remirez, M Echaide, M Martinez‐Aguillo… - EMBO …, 2023 - embopress.org
Recent studies highlight the importance of baseline functional immunity for immune
checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in a …
checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in a …
Senescent CD4 T cells unequivocally identify primary resistance and risk of hyperprogression to PD-L1/PD-1 immune checkpoint blockade in lung cancer
…, B Hernández-Marín, M Martínez-Aguillo… - BioRxiv, 2018 - biorxiv.org
The majority of lung cancer patients are intrinsically refractory to PD-L1/PD-1 blockade
monotherapy. There is recent evidence indicating that this therapy can have serious deleterious …
monotherapy. There is recent evidence indicating that this therapy can have serious deleterious …
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
…, K Zaman, V Boni, J Arrondeau, M Martinez Aguillo… - 2019 - ascopubs.org
8506 Background: Lurbinectedin (L) is a novel anticancer drug that inhibits activated transcription
and induces DNA double-strand breaks, leading to apoptosis. Methods: A multicenter …
and induces DNA double-strand breaks, leading to apoptosis. Methods: A multicenter …
Potent clinical predictive and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer
…, M Garnica, A Remirez, M Martinez-Aguillo… - MedRxiv, 2022 - medrxiv.org
Recent studies highlight the importance of baseline functional immunity for efficacious
immune checkpoint blockade therapies. High-dimensional systemic immune profiling was …
immune checkpoint blockade therapies. High-dimensional systemic immune profiling was …
